Navigation Links
Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
Date:3/7/2011

their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

As we expanded our number of Tumorgraft models, we began to offer leading pharmaceutical and biotechnology companies the benefits of our Tumorgraft Technology Platform for their pharmaceutical development programs.  We provide Translational Oncology Solutions, or TOS, (previously referred to as Preclinical eValuation services) that we believe are predictive of clinical outcomes and that might provide for a faster and less expensive path to drug approval.  These services utilize Tumorgrafts to evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents.  TOS also includes biomarker discovery and the identification of novel drug combinations.  We began deriving revenues from our TOS services in fiscal 2009 and completed our first full year of business in fiscal 2010.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsbiotechnology.com.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Co
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Additions to its Management Team
2. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
3. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
4. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
7. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
8. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
11. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
Breaking Biology Technology:IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... and Clinical Studies Demonstrate Activity of ... Agent against Gram-Positive Bacteria, CHICAGO, Sept. 18 ... THRX ) announced today results with the,investigational ... skin and skin structure infections,(cSSSIs) from a controlled ...
... Preclinical Animal Data Demonstrates Selective Survival Advantage of ... ZFN-Treated Immune Cells after HIV Infection, ... (Nasdaq: SGMO ) announced today the presentation of ... resistant to,HIV infection by treatment with zinc finger DNA-binding ...
... Research - the New ISI Web of Knowledge - ... Institutions Throughout the Country, PHILADELPHIA and LONDON, Sept. ... TOC ; TSX: TOC) and,leading provider of information ... that Spain,s La Fundacion Espanola,para la Ciencia y la ...
Cached Biology Technology:Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 6Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3
(Date:9/29/2014)... , Sept. 29, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... S. Miceli has been named the Company,s Vice-President ... Gino Pereira as Chief Financial Officer. Mr. ... Executive Officer and as a Director. Mr. ...
(Date:9/29/2014)... safely tolerate treatment with cells cultured from human placental ... journal Multiple Sclerosis and Related Disorders . The ... conducted by researchers at Mount Sinai, Celgene Cellular Therapeutics ... institutions. , While designed to determine safety of ... that a preparation of cultured cells called PDA-001 may ...
(Date:9/28/2014)... by scientists at the University of California, Santa Cruz, ... within the genomes of primates drove the evolution of ... in every cell of our bodies. , The ... "retrotransposons" (a.k.a. "jumping genes") and the genes that have ... have, for the first time, identified genes in humans ...
Breaking Biology News(10 mins):NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2Human genome was shaped by an evolutionary arms race with itself 2Human genome was shaped by an evolutionary arms race with itself 3Human genome was shaped by an evolutionary arms race with itself 4
... is well known that animals use song as a way ... developed an unusual way of scaring off predators ?by singing ... Andrews discovered that wild gibbons in Thailand have developed a ... singing for survival, the gibbons appear to use the song ...
... replication within resident immune cells of the testis, providing ... even after effective highly active antiretroviral therapy. The related ... to human immunodeficiency virus-1 infection in situ and in ... of Pathology. , According to the most recent ...
... timing of food availability, researchers have identified the first ... Period 2, is a key component of the circadian ... of the University of Fribourg and Etienne Challet of ... 24th issue of the journal Current Biology, published by ...
Cached Biology News:Singing for survival 2Singing for survival 3Human testis harbors HIV-1 in resident immune cells 2Circadian gene helps the brain predict mealtime 2
... operational costs. More efficient interfacing with ... sample volumes. Industry demands for benefits ... microbore chromatography for routine applications. Standard ... satisfy the need to operate with ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
... Hepta adaptor for the PDS-1000 He biolistic system ... than the standard system. It fits into the ... it splits the helium shock wave over 7 ... tungsten particles over this larger area, the system ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: